agents were better than placebo. In CC, the number needed to treat (NNT) ranged from 4 (95% CI 3-7) for lubiprostone to 6 (5-8) , for linaclotide and 6 (5-9) for prucalopride. 5 For IBS-C, the NNT was 13 for lubiprostone and 7 (5) (6) (7) (8) , for linaclotide; prucalopride has not been studied in IBS-C. Of note, the NNT for polyethylene glycol in CC is 3 (2-4). Colonic transit was not evaluated in any of these trials. Hence, the efficacy of these drugs in slow transit constipation is unknown. Since placebo, not over-the-counter laxatives, were the comparator in all studies, head-to-head comparisons of these drugs versus simple laxatives are unavailable. Finally, failure to respond to over-the-counter laxatives was an eligibility criterion for studies with prucalopride but not for studies with lubiprostone, linaclotide, or plecanatide. Hence, the incremental utility of these agents over traditional laxatives is unknown. While pelvic floor biofeedback therapy is beneficial to defecatory disorders, the technique is operator dependent and not widely available. Indeed, even in a clinical trial from an experienced center, the response rate was only 61%. 6 Hence, a substantial proportion of patients have refractory constipation. We would define refractory constipation as an inadequate improvement in constipation symptoms evaluated with an objective scale, despite adequate therapy (ie, pharmacological or behavioral), which is guided by the underlying pathophysiology, also including combinations of different drugs. A practical definition of adequate duration is a minimum of 4 weeks for each drug and 3 months for pelvic floor biofeedback therapy. The clinical decision-making tool
proposed by an international consensus statement provides a simple and effective approach for evaluating the response to therapy. 7 The 4 week criterion is underpinned by the recognition that most patients who response to medications for constipation generally do so within 4 weeks 8 and this is also reflected in NICE guidance. 9 In clinical practice, currently, a colectomy is the next step for patients with refractory slow transit constipation who do not have a DD. Before surgery, a colonic manometry with or without barostat testing should be performed, where available, to identify colonic inertia, which is defined by impaired responses to a meal and pharmacological stimulation with bisacodyl or neostigmine. 10 This review appraises the current options for these patients.
| THE AVAIL AB LE TRE ATMENT OP TI ON S FOR REFR AC TORY CON S TIPATI ON

| The role of rectal irrigation
Trans-anal irrigation (TAI), also known as rectal irrigation, involves the instillation of water into the rectum to facilitate a washout of the rectum and sigmoid colon. The volume of water may vary (typically between 70 mL and 1000 mL) and there are now a variety of devices that can be used to achieve this. 13 While the initial and most subsequent reports were in patients with neurogenic bowel dysfunction, [14] [15] [16] it has also been studied in patients with non-neurological chronic constipation (CC) and fecal incontinence. 17 It is increasingly used in units that manage patients with CC. Since these are uncontrolled, mostly small and retrospective reports, its true efficacy is not understood.
A recent systematic review and meta-analysis of TAI in CC 18 identified seven studies including a total of 254 CC patients. All studies were uncontrolled and all but two were retrospective. The proportion of patients reporting a positive outcome of therapy varied from 30% to 65%. A fixed, rather than random, effect analysis of proportions gave a pooled response rate of 50% (95% CI 44%-57% Anecdotally, some patients report an improved urge to defecate after TAI.
TAI is contra-indicated in early pregnancy and where there is an increased risk of perforation (eg, colitis, cancer, recent resection).
Rectal perforation is uncommon (ie, approximately 1 in 500 000 irrigations) and has been mostly reported in bedridden patients. 21, 22 Over 50% of patients who discontinue therapy do so because they find it too inconvenient or because they experience technical difficulties (eg, water leakage, catheter expulsion, a burst balloon, and peri-anal discomfort). 23 While TAI is relatively expensive, it reduces the cost of care and is cost-effective in patients with spinal cord injury and constipation. 24 In summary, TAI is useful for managing some patients with refractory chronic constipation. However, prospective studies are required to assess its efficacy, identify predictive factors, determine the relative value of different methods of irrigation (eg, low volume vs high volume), and evaluate the cost-effectiveness. A current multi-center UK study (CAPACITY 2) is designed to answer some of these questions. 25 
| The role of surgery or sacral nerve stimulation
Exemplifying primum non nocere, surgery is reserved for a carefully selected, small proportion of patients with medically refractory chronic constipation (Table 1) . Surgery can restore anatomy, but not, with the possible exception of neural implants, modify neuromuscular functions. In contrast to other therapies, surgery has the potential for irreversible harm.
The outcomes of all main procedures for CC were systematically reviewed in 2017 [26] [27] [28] [29] [30] [31] [32] (all full open access) ( Table 1 ). In brief, the ev- Table 1 . These differences underscore the differences between global satisfaction ratings and rigorous validated outcomes, which were only used in a few studies.
Similarly, the beneficial outcomes of sacral neuromodulation for CC, claimed on the basis of observational data, have been completely refuted by 2 subsequent RCTs that both show no benefit of this procedure over sham stimulation. 34, 35 Detailed summary evidence statements derived from these reviews were used to develop (by European expert consensus) a series of graded practice recommendations that address patient selection, procedural considerations and patient counselling. 29 Counselling should consider the balance between benefits and harms, as underscored by recent media reports of the uncommon but significant harms caused by placement of pelvic mesh during rectopexy (infection, erosion, and chronic pain) 36, 37 and to a lesser extent, the use of stapling devices to excise the rectal wall (STARR procedure) (chronic pain, urgency, and incontinence). 37 Over and above the introduction of enhanced consent processes for such procedures, 36 it simply cannot be stressed enough that the selection of patients for potentially harmful surgery must be made with the expectation that their symptoms will be improved by surgery. This Pooled estimates based on random effects models with (95% CI).
c Numerous other harms are listed in full reviews (see also text).
TA B L E 2 Review of currently published literature regarding use of PEC in constipation disorders 33 Prior to colectomy, a temporary loop ileostomy may help ascertain whether symptoms emanate from the small intestine or colon. Similarly, the criteria for operating on a rectocele must consider whether symptoms are those typical of a rectocele, that is, vaginal bulging with obstructed defecation and partial resolution with splinting, and whether a large rectocele is both clinically evident and confirmed by diagnostic radiology.
If such criteria are met, and relative contraindications are absent, for example, smoking and obesity, then a reasonable chance of success can be anticipated. This will not, however, be true of a patient with chronic pelvic pain and dyssynergia who happens to also have a rectocele. A further point in relation to pelvic organ prolapse syndromes is that the 3 organs that immediately depend for their anatomical disposition on the pelvic floor (bladder, vagina, and anorectum) should not be addressed by a silo approach between surgical specialities. To neglect the opportunity to correct anatomy of multiple pelvic compartments, for example, synchronous sacrocolpopexy and rectopexy may unnecessarily subject patients to further, more complex, re-operative surgery.
These points, taken together, reaffirm the need for great caution when recommending surgery for chronic constipation. They also underscore the importance of a meticulous assessment of clinical features supplemented, as appropriate, with physiological and radiological tests, followed by multidisciplinary coordination of management preferably in accredited specialist units 36 before surgery is contemplated. However, 42% (25 of 60) of patients had complications, ranging from mild local infection to fecal peritonitis. Thereafter, there were 2 reviews of PEC in 76 patients with sigmoid volvulus (56 patients) or chronic intestinal pseudo-obstruction (20 patients). 40, 41 In these reports, the outcomes evaluated qualitatively were good with relatively low morbidity (21% for sigmoid volvulus, 30% CIPO), and mortality (5% for both).
| The role of PEC
Strijbos et al. 12 reviewed their experience with this procedure.
Their experience and other reports are summarized in Table 2 .
The procedure was successful in 122 of 127 patients with refractory constipation. These studies included patients with spinal cord injury and opioid use. Some studies categorized patients into slow-transit constipation or a defecatory disorder. During the follow-up period, which ranged from 1 to 89 months, 14 of 122 patients (11%) died. However, none of the deaths seemed directly attributable to the procedure. In one study, 7 of 27 patients (26%) died after PEC. 42 However, this report included patients with constipation or sigmoid volvulus or chronic intestinal pseudoobstruction; 5 of these 7 patients died due to unrelated causes (ie, pneumonia and cancer) and the remaining 2 patients developed Hence, long term follow-up is limited; only 5 of 122 patients with PEC still in situ were followed up for more than 3-4 years 43 (maximum median follow-up was 43 months among all other studies).
In this study of 21 patients who had PEC between 1997 and 2006, 52% of tubes were removed by 2014. 42 Only 5 patients were alive with the tube with follow-up between 11 and 17 years. In another large series, the tube remained in situ in only 2 of 27 patients, with these patients only followed up for 7 and 10 months. 42 .
How does PEC compare with surgical interventions for constipation? A systematic review of the latter suggested that 86% of patients were satisfied after surgery, 28 20%-30% had complications, and 13% required re-operation. By comparison, 30% of patients have complications after the Malone procedure.
12
Since PEC can be performed under local anesthesia and conscious sedation, it might be preferred to surgery in patients who have a higher surgical risk due to co-morbidities. Also, PEC is reversible. More evidence is required to weigh the risk: benefit profile of PEC alone and versus surgery.
| CON CLUS IONS
While newer pharmacological options and pelvic floor biofeedback therapy are effective for chronic constipation, a substantial proportion of patients are refractory to these therapies. A majority of patients report high global satisfaction rates after colectomy for slow transit constipation. However, few studies of colectomy, and other options, including PEC and rectal irrigation, used rigorous validated outcomes.
Indeed, the evidence for PEC and rectal irrigation is mostly based on retrospective case reports. Hence, rigorous, evidence-based trials of minimally invasive, and surgical approaches for refractory constipation are necessary to assess the risk: benefit profile of these approaches and to identify the factors that predict the response to treatment. These studies should include patients who satisfy the criteria for refractory constipation as proposed in this review, and in whom the results of prior therapies have been documented. Until then, clinicians should apply the current evidence to use pharmacological and behavioral treatments, utilizing rectal irrigation in patients not responding to these treatment, reserving surgery to selected cases identified in referral centers. While PEC may work for some patients, it should, pending further studies, only be considered in the context of clinical trials and in centers with endoscopists who have experience with placement.
AUTHOR CONTRIBUTI ON S
MC conceptualized the review, MC and AEB wrote the introduction and made critical revisions to the manuscript, VWS wrote the section on PEC, collated all the different parts and wrote the conclusions, YY and AE wrote the section on rectal irrigation, CK wrote the section on surgical treatment. 
CO N FLI C T O F I NTE R E S T S
